Actors Benedix Ramos (left) and Justin Basobas are among the regular characters in the six episode series, “All the Things I Leave You (Patawid).” The trailer has gone viral with more than 4 million ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) versus ...

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 – CABOMETYX ...

Technological advancement has become a leading cause of economic growth and global influence. The innovation nations, research nations, and technologically advanced nations are setting the future ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Google is sharing more information on how Chrome operates when Android mobile users enable Advanced Protection, highlighting strong security improvements. The tech giant recently extended its Advanced ...

LONDON, ENGLAND - APRIL 28: Zero emission branding is displayed on a Kia all electric British Transport Police car is displayed during the Fully Charged Live UK at Farnborough International on April ...

It was recently discovered that Microsoft is working on a new Settings section for Windows 11 called "Advanced Settings." Initially unearthed in a Windows Server preview build, the page is now rolling ...

Microsoft has announced Copilot Actions, which will be able to browse the web for you. It performs tasks like booking tickets, making reservations, and even purchasing items. It can also look up the ...

The FDA approval—adding to five previous approvals for CABOMETYX—is based on results from CABINET, a phase 3 pivotal trial evaluating CABOMETYX compared with placebo in two cohorts of patients with ...

Cabozantinib significantly delayed disease progression in advanced pancreatic and extra-pancreatic neuroendocrine tumors, as shown in the phase 3 CABINET trial. The trial demonstrated a median PFS of ...